JP2025508075A5 - - Google Patents
Info
- Publication number
- JP2025508075A5 JP2025508075A5 JP2024553452A JP2024553452A JP2025508075A5 JP 2025508075 A5 JP2025508075 A5 JP 2025508075A5 JP 2024553452 A JP2024553452 A JP 2024553452A JP 2024553452 A JP2024553452 A JP 2024553452A JP 2025508075 A5 JP2025508075 A5 JP 2025508075A5
- Authority
- JP
- Japan
- Prior art keywords
- heavy chain
- constant region
- amino acid
- chain constant
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263268945P | 2022-03-07 | 2022-03-07 | |
| US63/268,945 | 2022-03-07 | ||
| PCT/US2023/063821 WO2023172890A2 (en) | 2022-03-07 | 2023-03-07 | Anti-ilt2 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508075A JP2025508075A (ja) | 2025-03-21 |
| JP2025508075A5 true JP2025508075A5 (enExample) | 2026-03-12 |
Family
ID=87935886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553452A Pending JP2025508075A (ja) | 2022-03-07 | 2023-03-07 | 抗ｉｌｔ２抗体及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250109201A1 (enExample) |
| EP (1) | EP4490196A2 (enExample) |
| JP (1) | JP2025508075A (enExample) |
| KR (1) | KR20250004950A (enExample) |
| CN (1) | CN119365487A (enExample) |
| AU (1) | AU2023231622A1 (enExample) |
| CA (1) | CA3254318A1 (enExample) |
| IL (1) | IL315487A (enExample) |
| MX (1) | MX2024010982A (enExample) |
| WO (1) | WO2023172890A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025059304A2 (en) * | 2023-09-12 | 2025-03-20 | Agenus Inc. | Methods of treating cancer using ilt2 antibodies and combination therapies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1678195A4 (en) * | 2003-10-08 | 2008-04-23 | The Feinstein Inst Medical Res | METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTIC B-CELL LEUKEMIA |
| WO2018148494A1 (en) * | 2017-02-09 | 2018-08-16 | Bluefin Biomedicine, Inc. | Anti-ilt3 antibodies and antibody drug conjugates |
| MX2021015024A (es) * | 2020-04-28 | 2022-01-18 | Univ Rockefeller | Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos. |
| MY209480A (en) * | 2020-05-01 | 2025-07-11 | Ngm Biopharmaceuticals Inc | Ilt-binding agents and methods of use thereof |
-
2023
- 2023-03-07 IL IL315487A patent/IL315487A/en unknown
- 2023-03-07 CN CN202380038440.3A patent/CN119365487A/zh active Pending
- 2023-03-07 AU AU2023231622A patent/AU2023231622A1/en active Pending
- 2023-03-07 JP JP2024553452A patent/JP2025508075A/ja active Pending
- 2023-03-07 EP EP23767599.6A patent/EP4490196A2/en active Pending
- 2023-03-07 KR KR1020247032336A patent/KR20250004950A/ko active Pending
- 2023-03-07 CA CA3254318A patent/CA3254318A1/en active Pending
- 2023-03-07 WO PCT/US2023/063821 patent/WO2023172890A2/en not_active Ceased
-
2024
- 2024-09-06 MX MX2024010982A patent/MX2024010982A/es unknown
- 2024-09-06 US US18/827,368 patent/US20250109201A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12331119B2 (en) | Modified Fc fragment, antibody comprising same, and application thereof | |
| AU2016274485B2 (en) | LAG-3-binding molecules and methods of use thereof | |
| KR102761886B1 (ko) | Pd-1-결합 분자 및 그것의 사용 방법 | |
| JP2021525082A5 (enExample) | ||
| JP2018035138A5 (enExample) | ||
| CA3020864A1 (en) | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| JP2023528350A5 (enExample) | ||
| TWI814715B (zh) | Ａｄａｍ９結合分子及使用其的方法 | |
| US20230174648A1 (en) | Sirp alpha and sirp beta 1 antibodies and uses thereof | |
| EP3880707A1 (en) | HUMANIZED ANTI-SIRPa ANTIBODIES | |
| JP2021534797A5 (enExample) | ||
| JP2022545741A5 (enExample) | ||
| JP2023522730A5 (enExample) | ||
| JP2024515396A5 (enExample) | ||
| JP2024540148A5 (enExample) | ||
| JP2023523016A5 (enExample) | ||
| JP2025186381A (ja) | Ｃｄ１３７結合分子及びその使用 | |
| JP2025508075A5 (enExample) | ||
| CA3226306A1 (en) | Novel multi-specific molecules | |
| JP7192042B2 (ja) | Ｌａｇ‐３結合分子及びその使用方法 | |
| CA2986953C (en) | Lag-3-binding molecules and methods of use thereof | |
| NZ769634A (en) | Anti-sirpa antibodies and methods of use thereof | |
| RU2023123926A (ru) | Антитела к vista и их применение | |
| NZ769634B2 (en) | Anti-sirpa antibodies and methods of use thereof | |
| NZ775277B2 (en) | Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof |